STOCK TITAN

Cadrenal Therapeutics (CVKD) Form 4 Filings

CVKD NASDAQ

Here are the Form 4 insider transactions from Cadrenal Therapeutics, Inc. (CVKD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A Form 4 covers the transactions officers, directors and large holders report, so if you follow CVKD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVKD filings page.

Rhea-AI Summary

Cadrenal Therapeutics, Inc. Chairman and CEO Quang X. Pham received a direct award of 200,000 stock options on October 9, 2026, under the 2022 Successor Equity Incentive Plan. The options were fully vested and immediately exercisable on the grant date. Their $0.91 exercise price equaled the common stock’s closing price on October 9, 2026, and they expire October 8, 2036. The reported post-transaction position was 200,000 options.

Rhea-AI Summary

Cadrenal Therapeutics, Inc. director Lee Scott Golden was granted 75,000 stock options on October 9, 2026, under the company’s 2022 Successor Equity Incentive Plan. The options were fully vested and immediately exercisable on the grant date, with an exercise price of $0.91 per share and an expiration date of October 8, 2036. They cover 75,000 shares of common stock, and the exercise price equaled the closing price of the company’s common stock on the grant date.

Rhea-AI Summary

Cadrenal Therapeutics, Inc. director John Raymond Murphy received a grant of 75,000 stock options on October 9, 2026, covering 75,000 common shares. The options were fully vested and immediately exercisable on the grant date, with a $0.91 exercise price and an expiration date of October 8, 2036.

Rhea-AI Summary

Cadrenal Therapeutics, Inc. (CVKD) reported that Chief Operating Officer Jeffrey Scott Cole received a grant of 150,000 stock options on October 9, 2026, under the company's 2022 Successor Equity Incentive Plan. The options are reported as directly held and relate to 150,000 shares of common stock.

Rhea-AI Summary

Cadrenal Therapeutics, Inc. director Glynn Wilson acquired 75,000 stock options on October 9, 2026. The options were fully vested and immediately exercisable on the grant date, carried a $0.91 exercise price, and expire October 8, 2036.

Rhea-AI Summary

Cadrenal Therapeutics Chairman and CEO Quang Pham, a more than 10% owner, reported an open-market sale of 7,400 shares of common stock on June 29, 2026 at a weighted average price of $3.03 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025.

Following the sale, Pham directly holds 98,589 shares of Cadrenal common stock. He also has indirect ownership of 200,000 shares held by The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power and his child is the sole beneficiary.

Rhea-AI Summary

Cadrenal Therapeutics, Inc. director and Chairman, CEO and Interim CFO Quang X. Pham reported open-market sales of the company’s common stock. He sold 2,127 shares at $3.00 per share and 9,029 shares at a weighted average of $3.05 per share in late June 2026.

The sales were made under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following these transactions, Pham held 105,989 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, for which he has sole voting and dispositive power.

Rhea-AI Summary

Cadrenal Therapeutics director and CEO Quang Pham reported open-market stock sales under a pre-set trading plan. He sold 9,167 shares of common stock on June 22, 2026 at a weighted average price of $3.55 per share and 2,277 shares on June 23, 2026 at a weighted average price of $3.20 per share, totaling 11,444 shares sold. These transactions were executed pursuant to a Rule 10b5-1 trading arrangement adopted on September 25, 2025. After the sales, he held 117,145 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power.

Rhea-AI Summary

Cadrenal Therapeutics Chairman and CEO Quang X. Pham reported open-market sales of 4,126 shares of Common Stock at weighted average prices around $3.16–$3.18 per share. The sales on June 16–17, 2026 were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 25, 2025.

After these transactions, Pham holds 128,589 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power. The reported sales represent a small portion of his overall reported holdings and do not involve any derivative exercises.

Rhea-AI Summary

Cadrenal Therapeutics director and CEO Quang X Pham reported open-market sales of company stock. He sold a total of 18,124 shares of Cadrenal Therapeutics, Inc. common stock in three transactions on June 11, 12 and 15, 2026, at weighted average prices of $4.12, $3.94 and $3.58 per share.

The sales were made under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following these transactions, Pham holds 132,715 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power.

Rhea-AI Summary

Cadrenal Therapeutics, Inc. Chairman, CEO and Interim CFO Quang X Pham reported open-market sales of a total of 22,385 shares of common stock over three days. Shares were sold at weighted average prices of about $4.38 on June 8, $4.06 on June 9, and $4.21 on June 10, in transactions described as carried out under a Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following these sales, Pham holds 150,839 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, for which he has sole voting and dispositive power.

Rhea-AI Summary

Cadrenal Therapeutics, Inc. CEO and Chairman Quang X. Pham reported open-market sales of a total of 8,285 shares of common stock on June 3–5, 2026 at weighted average prices of $4.26, $4.41 and $4.42 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following the transactions, he holds 173,224 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, for which he has sole voting and dispositive power.

Rhea-AI Summary

Cadrenal Therapeutics, Inc. CEO and Chairman Quang Pham reported small open-market sales of company common stock. He sold 303 shares on May 29, 2026 at a weighted average price of $5.01 per share and 349 shares on June 2, 2026 at a weighted average price of $4.46 per share, totaling 652 shares. The sales were executed under a pre-arranged Rule 10b5-1 trading arrangement. After these transactions, Pham holds 181,509 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power.

Rhea-AI Summary

Cadrenal Therapeutics, Inc. CEO and Chairman Quang X Pham reported open-market sales of 12,763 shares of common stock. The sales occurred on May 11, May 12, and May 28, 2026, at reported weighted average prices of $5.76, $5.28, and $4.93 per share.

The footnotes state these transactions were made under a Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following the latest sale, Pham holds 182,161 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power. The filing also corrects an earlier understatement of indirect holdings on a prior Form 4.

Rhea-AI Summary

Cadrenal Therapeutics CEO and Chairman Quang Pham reported an open-market sale of 1,165 shares of Common Stock on May 22, 2026 at a weighted average price of $5.69 per share, executed as an "S" code transaction.

The sale was made pursuant to a Rule 10b5-1 trading arrangement adopted on September 25, 2025, meaning it was pre-arranged. After the sale, Pham directly owns 194,924 shares of Cadrenal Therapeutics common stock and indirectly holds 20,000 shares through The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power.